BLUE BELL, Pa.–(Business Wire)–
Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of
preventive and therapeutic vaccines against cancers and infectious diseases,
announced today that president and CEO, Dr. J. Joseph Kim will present a
corporate update on its DNA vaccines for influenza, HIV and cancer and its
vaccine delivery technology at the following investor conferences:
Noble Financial Sixth Annual Equity Conference
June 7th, 2010
Hollywood, FL
Presentation: June 7th, 2010, 9:00 a.m. ET
A live and archived webcast will be accessible on Inovio`s website at www.inovio.com.
Ninth Annual Needham Healthcare Conference
June 9 – 10, 2010
New York, NY
Presentation: June 9, 2010, 2:40 p.m. ET
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals is focused on the development of a new generation of
vaccines, called DNA vaccines, to prevent and treat cancers and infectious
diseases. The company`s SynCon “universal” vaccines are designed to provide
broad cross-strain protection against known as well as newly emergent strains of
pathogens such as influenza. Inovio`s proprietary electroporation delivery
technology has been shown by initial human data to be safe and significantly
increase gene expression and immune responses. Inovio`s clinical programs
include HPV/cervical cancer (therapeutic), avian flu, and HIV vaccines. Inovio
is developing its universal influenza vaccines in collaboration with scientists
from the University of Pennsylvania, National Microbiology Laboratory of the
Public Health Agency of Canada, and NIH`s Vaccine Research Center. Other
partners and collaborators include Merck, ChronTech, University of Southampton,
National Cancer Institute, and HIV Vaccines Trial Network. More information is
available at www.inovio.com.
This press release contains certain forward-looking statements relating to our
business, including our plans to develop electroporation-based drug and gene
delivery technologies and DNA vaccines and our capital resources. Actual events
or results may differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical studies,
clinical trials and product development programs (including, but not limited to,
the fact that pre-clinical and clinical results referenced in this release may
not be indicative of results achievable in other trials or for other
indications, that results from one study may not necessarily be reflected or
supported by the results of other similar studies and that results from an
animal study may not be indicative of results achievable in human studies), the
availability of funding to support continuing research and studies in an effort
to prove safety and efficacy of electroporation technology as a delivery
mechanism or develop viable DNA vaccines, the adequacy of our capital resources,
the availability or potential availability of alternative therapies or
treatments for the conditions targeted by the company or its collaborators,
including alternatives that may be more efficacious or cost-effective than any
therapy or treatment that the company and its collaborators hope to develop,
evaluation of potential opportunities, issues involving patents and whether they
or licenses to them will provide the company with meaningful protection from
others using the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on rights of others
or can withstand claims of invalidity and whether the company can finance or
devote other significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of the
company`s technology by potential corporate or other partners or collaborators,
capital market conditions, our ability to successfully integrate Inovio and VGX
Pharmaceuticals, the impact of government healthcare proposals and other factors
set forth in our Annual Report on Form 10-K for the year ended December 31,
2009, our Form 10-Q for the three months ended March 31, 2010, and other
regulatory filings from time to time. There can be no assurance that any product
in Inovio`s pipeline will be successfully developed or manufactured, that final
results of clinical studies will be supportive of regulatory approvals required
to market licensed products, or that any of the forward-looking information
provided herein will be proven accurate.
Investors:
Inovio Pharmaceuticals
Bernie Hertel, 858-410-3101
bhertel@inovio.com
or
Media:
Richardson & Associates
Jeff Richardson, 805-491-8313
jeff@richardsonglobalpr.com
Copyright Business Wire 2010